This is not only because of the high frequency of adverse cytogenetic (e.g., -7/-7q, -5/-5q, -3/-3q, -17/-17p, complex and/or monosomal karyotypes) and molecular lesions (e.g., TP53 mutations), but also due to the sequelae of prior chemotherapy and sometimes persistent primary disease, particularly metastatic cancer or lymphoma. The gene discussed is TP53; the disease is lymphoma.